Hexarelin 5 mg

Peptide Hubs Hexarelin

Hexarelin (Examorelin) stands as the most potent synthetic Growth Hormone Releasing Peptide (GHRP) available for research, presented in a 5 mg lyophilized powder vial. This hexapeptide is renowned in endocrine research for its unparalleled ability to stimulate a massive, rapid release of endogenous growth hormone (GH) from the pituitary gland. An independent third-party lab test confirms an exceptional purity of 6.80 mg per vial—a 36% overfill that underscores both superior quality and generous manufacturing. For bodybuilders, athletes, and advanced peptide researchers, Hexarelin offers the definitive model for investigating the upper limits of GH secretagogue potency. Its extreme effectiveness is balanced by a distinct hormonal side effect profile, making it a compelling subject for comparative studies on GHRP selectivity, desensitization, and the acute effects of supraphysiological GH pulses.

Hexarelin Composition

Each sterile 2 mL vial contains 5 mg of synthetic Hexarelin with the sequence: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. This hexapeptide is characterized by a unique D-2-methyl-tryptophan substitution at position 2, which confers extraordinary binding affinity and resistance to degradation. The product is supplied as a pure, white lyophilized powder without excipients, requiring reconstitution with bacteriostatic water before use. This highly stable formulation ensures researchers work with the most potent GHRP analog in its active form.

Bodybuilding and Athletic Research Benefits

In research models, Hexarelin's primary value lies in its ability to generate the largest acute GH pulse among GHRPs. Investigational benefits focus on the consequences of this powerful stimulation: potentially maximal stimulation of protein synthesis and nitrogen retention for muscle growth support; profound lipolytic (fat-burning) effects due to high GH spikes; accelerated recovery from training through amplified repair signals; and potential acute increases in strength and power output. For researchers studying the dose-response relationship of GH on performance or body composition, Hexarelin provides the most powerful "trigger" available, allowing exploration of effects that may not be achievable with less potent secretagogues.

Therapeutic and Research Indication

Hexarelin has been clinically studied as a diagnostic agent for growth hormone deficiency and in research contexts for cardiac and metabolic conditions. Its mechanism is potent ghrelin receptor (GHS-R1a) agonism, but with higher efficacy and less selectivity than other GHRPs. According to pharmacological comparisons referenced by the National Institutes of Health (NIH), Hexarelin exhibits the highest GH-releasing potency among its peptide peers.

Mechanism of Action: Maximum Efficacy Ghrelin Receptor Agonism

Hexarelin binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) with the highest affinity and efficacy of any GHRP. This binding produces an exceptionally robust activation of the inositol phosphate (IP3) pathway, leading to a massive calcium influx and exocytosis of stored GH vesicles. Unlike more selective GHRPs (e.g., Ipamorelin), Hexarelin's interaction with the receptor is less specific, leading to significant cross-activation of pathways that increase prolactin and cortisol secretion. It may also have unique, non-ghrelin receptor-mediated effects that contribute to its extreme potency. This makes it a "full efficacy" agonist ideal for research on maximal physiological GH response.

Dosage for Research (Men)

Due to its extreme potency, Hexarelin research dosing is conservative. Common investigative doses range from 1 mcg to 2 mcg per kilogram of body weight, administered via subcutaneous injection. This typically translates to 70-140 mcg for an average subject. Doses above 100-200 mcg are rarely needed and increase side effect risk. It is typically administered once daily or every other day to mitigate rapid desensitization (tachyphylaxis) of the pituitary response. Pre-bedtime administration is common to amplify the nocturnal GH surge. Research cycles are often shorter (4-8 weeks) with planned breaks to restore sensitivity.

Dosage for Research (Women)

Research dosing for female subjects follows the same microgram-per-kilogram principle (1-2 mcg/kg), often initiating at the lower end. The potent hormonal effects, including prolactin elevation, require careful consideration in female research design. Conservative dosing and close monitoring are essential. The rapid desensitization phenomenon is equally relevant.

Active Life and Half-Life

Hexarelin has a plasma half-life of approximately 30-60 minutes, similar to other GHRPs. However, the GH pulse it generates is significantly larger and may have a longer duration of elevated levels. The most critical pharmacokinetic consideration is the rapid development of tachyphylaxis—the pituitary's GH response diminishes sharply with repeated daily dosing, often within 1-2 weeks. This necessitates intermittent dosing schedules (e.g., 5 days on, 2 days off) in longer-term research to preserve efficacy.

Hexarelin Side Effects

Research observations are pronounced due to its potency: strong flushing, warmth, and headache associated with the massive GH pulse; significant increases in prolactin and cortisol levels, which are more marked than with GHRP-2 or GHRP-6; moderate hunger stimulation (though less than GHRP-6); and a high likelihood of pituitary desensitization with frequent use. Injection site reactions are possible. The hormonal side effects (prolactin/cortisol) are a defining characteristic and a key research variable.

Contraindications and Precautionary Measures

Hexarelin is contraindicated in research involving subjects with a history of or predisposition to prolactin-sensitive conditions (e.g., prolactinoma) or cortisol-related disorders. It should be avoided in subjects with active neoplasms. Its use in research with female subjects requires particular caution due to prolactin's effects on the menstrual cycle. The potential for rapid desensitization must be factored into study design. Hexarelin is for advanced laboratory research only under appropriate oversight.

Overdosage in Research

Exceeding the low microgram-per-kilogram dosing range will dramatically amplify side effects: severe flushing, headache, nausea, and pronounced elevations in prolactin and cortisol. Chronic overdosage could theoretically contribute to symptoms of hyperprolactinemia (e.g., lactation, sexual dysfunction) and hypercortisolism. Adherence to the strict 1-2 mcg/kg dosing is critical for both safety and to avoid accelerating pituitary desensitization.

Hexarelin Stack/Cycle for Research

Hexarelin is primarily researched as a standalone agent to study maximal GH release or in specific comparative stacks. Due to its desensitizing nature, it is less suited for long-term combination stacks.

• CJC-1295 No DAC can be studied with Hexarelin for the *theoretically* largest possible GH pulse, but this combination is for short-term research only due to extreme potency and desensitization risk.
• Ipamorelin serves as the perfect comparator in research on selectivity—contrasting Hexarelin's potent, broad hormonal effects with Ipamorelin's clean, selective profile.
• GHRP-2 for direct comparison of high-potency GHRPs, evaluating differences in hunger stimulation and hormonal side effect profiles.
• Tesamorelin to compare a potent GHRP-triggered GH release with a sustained GHRH analog approach focused on visceral fat.
• Sermorelin for research comparing a synthetic GHRP's potent trigger (Hexarelin) with a natural-sequence GHRH's more physiological stimulation (Sermorelin).

Package Presentation

The product is supplied as one sterile glass vial containing 5 mg of Hexarelin as a white lyophilized powder. The vial is sealed with a rubber stopper and aluminum crimp to ensure sterility. The packaging is discreet and secure, appropriate for this high-potency research compound.

Storage

For long-term stability, store the lyophilized powder at or below -20°C (-4°F). For short-term use, refrigeration at 2-8°C (36-46°F) is acceptable. After reconstitution with bacteriostatic water, the solution must be refrigerated and used within 7-10 days. Due to its potency, precise handling and dilution are crucial to avoid dosing errors.

Hexarelin Referrers

Hexarelin's unique profile is documented in comparative endocrinology studies. Key references include papers that directly compare the GH-releasing potency, efficacy, and hormonal side effects of Hexarelin, GHRP-6, and GHRP-2. Research on tachyphylaxis (desensitization) with repeated Hexarelin administration is also crucial for designing appropriate dosing schedules. Investigators should consult this specialized literature to understand both the power and the limitations of this exceptional peptide.

Third-Party Lab Test

2026-01-12

View Result

6.80 mg